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Abstract: Ferrous sulphate (FS) is a cost effective, readily available iron supplement for iron deficiency
(ID). The pro-oxidant effect of oral ferrous iron is known to induce inflammation, causing gastric side-
effects and resulting in poor compliance. Curcumin is a potent antioxidant and has also been shown
to exhibit iron chelation in-vitro, although it is not established whether these effects are retained
in-vivo. The aim of this study was therefore to assess the influence of a formulated bioavailable form
of curcumin (HydroCurcTM; 500 mg) on acute iron absorption and status in a double blind, placebo-
controlled randomized trial recruiting 155 healthy participants (79 males; 26.42 years ± 0.55 and 76
females; 25.82 years ± 0.54). Participants were randomly allocated to five different treatment groups:
iron and curcumin placebo (FS0_Plac), low dose (18 mg) iron and curcumin placebo (FS18_Plac),
low dose iron and curcumin (FS18_Curc), high dose (65 mg) iron and curcumin placebo (FS65_Plac),
and high dose iron and curcumin (FS65_Curc). Participants were provided with the supplements
according to their relevant treatment groups at baseline (0 min), and blood collection was carried out
at 0 min and at 180 min following supplementation. In the treatment groups, significant difference
was observed in mean serum iron between baseline (0 min) and at end-point (180 min) (F (1, 144)
= 331.9, p < 0.0001) with statistically significant intra-group increases after 180 min (p < 0.0001) in
the FS18_Plac (8.79 µmol/L), FS18_Curc (11.41 µmol/L), FS65_Plac (19.09 µmol/L), and FS65_Curc
(16.39 µmol/L) groups. A significant difference was also observed between the two time points in
serum TIBC levels and in whole blood haemoglobin (HGB) in the treatment groups, with a significant
increase (1.55%/2.04 g/L) in HGB levels from baseline to end-point observed in the FS65_Curc group
(p < 0.05). All groups receiving iron demonstrated an increase in transferrin saturation (TS%) in
a dose-related manner, demonstrating that increases in serum iron are translated into increases in
physiological iron transportation. This study demonstrates, for the first time, that regardless of
ferrous dose, formulated curcumin in the form of HydroCurc™ does not negatively influence acute
iron absorption in healthy humans.
Keywords: curcumin; iron; ferrous sulphate; supplementation; nutrition; antioxidant
1. Introduction
Iron is an essential mineral nutrient that plays a key role in most biological processes
necessary to sustain life [1,2]. Iron deficiency (ID) is ranked as the most prevalent nutritional
deficiency [3] affecting around 30% of the global population, equating to over 2 billion
people [4,5]. ID is caused by inadequate dietary iron intake, as well as uptake by the
body to replenish iron that is lost daily mainly due to erythrocyte turnover in addition
to skin and gut cell sloughing. ID has been attributed to more than 60% of all anaemia
cases worldwide and is associated with reduced life expectancy, altered immune response,
developmental delays, and adverse pregnancy outcomes [3,6]. As iron is fundamental
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for growth and metabolism, ID even without anaemia can lead to impaired cognitive and
physical development in children, compromise physical and cognitive performance in
adults [3,7–9], and has been linked with fatigue [10], impaired quality of life [11], and
reduced mood [3,9].
Ferrous sulphate is considered the global ‘gold standard’ iron supplement due to its
extensive history of safe usage, documented effectiveness, and low cost [12,13]. However,
non-compliance with ferrous sulphate is as high as 50% due to negative gastrointestinal
(GI) effects attributed to iron intake [14–16]. The scope for ID treatment success is thus
limited often by poor compliance, particularly due to adverse GI effects such as constipa-
tion, diarrohea, and flatulence [3]. These GI symptoms are often accompanied by increased
inflammation as a consequence of excessive iron levels in the gut, facilitating the pro-
duction of detrimental reactive oxygen species (ROS) and consequent damage to the gut
mucosa [17].
Antioxidants can counteract the effects of ROS and have therefore generated interest
as molecules that could potentially ameliorate the pro-oxidant side-effects of iron [18,19].
Curcumin, a non-flavonoid polyphenol, is the most biologically active antioxidant com-
ponent in the rhizomatous spice Curcuma longa Linnaeus or turmeric [20]. Curcumin is
comprised of three curcuminoids: curcumin (80–75%), demethoxycurcumin (DMC; 20%),
and bisdemethoxycurcumin (BDMC; 2–5%) [21]. Curcumin has been extensively studied
for its ROS scavenging properties [22–25]. It acts as a free-radical chain breaker, capable of
donating hydrogen to ROS due to the presence of a hydroxyl group in its structure [26].
Curcumin also suppresses inflammation by mechanisms including downregulation of NF-
κB (nuclear factor kappa-light-chain-enhancer of activated B cells), thereby demonstrating
potent anti-inflammatory activity [27]. In addition to its antioxidant and anti-inflammatory
action, curcumin has also been shown to have neuroprotective properties, particularly
in relation to memory and cognition [28]. A meta-analysis of randomised controlled
trials confirmed a significant positive impact of curcumin supplementation on levels of
brain-derived neurotrophic factor (BDNF), a factor that affects cognitive function, learn-
ing, and memory [29]. Serum BDNF levels were also shown to increase significantly in
healthy adults following co-administration of iron and curcumin supplements recently
by Tiekou Lorinczova and co-workers [30]. The ability of curcumin to potentially counter
iron-mediated ROS generation and inflammation in the GI tract, in concert with its ability to
have a beneficial central effect, raises the intriguing possibility of co-administering iron and
curcumin supplements to limit the oxidative stress associated with iron supplementation
while synergising the beneficial effects of both molecules.
However, a body of research has shown whole turmeric or curcumin adversely affects
iron absorption and iron status in animal models [31–33]. Whole turmeric is known to
inhibit iron absorption by 20–90% in humans, reducing iron absorption in a dose-dependent
manner [34]. Curcumin and its analogue curcuminoids, DMC and BDMC, can exist in
two different forms depending on their environment, keto and enol [35]. In their enol
form, they are capable of accepting as well as donating hydrogen and have metal chelation
characteristics [36]. Curcumin binds ferric iron (Fe3+) to form a ferric–curcumin complex
that is dose-dependent and Fe3+ specific [37].
Despite these observations, there remains considerable ambiguity relating to the
nature of interactions between iron and curcumin in the context of absorption kinetics and
physiological effects in humans. The aim of this research study was therefore to assess
the influence of a formulated bioavailable form of curcumin (HydroCurc™) on acute iron
absorption in humans. To the best knowledge of the authors, curcuminoid constituents
have not been assessed previously in humans in relation to oral iron supplementation and
in relation to circulatory iron levels.
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2. Materials and Methods
2.1. Study Design
Briefly, 155 healthy participants were recruited in a double blind, placebo-controlled
randomized trial. Blocked, gender balanced randomisation was carried out using Study
Randomizer software [38], and sample size was calculated using G*Power 3.1.9.2 soft-
ware [39,40].
2.2. Ethics Approval and Study Registration
The study protocol was approved by the Faculty of Science and Technology Ethics
Committee, University of Westminster under the application identification: ETH1718-0907.
The study and the study protocol are registered with ClinicalTrials.gov (NCT04465851) and
public since 7 June 2020.
2.3. Inclusion and Exclusion Criteria
All participants enrolled in the study aligned with the inclusion criteria of being
healthy, aged 18–40 years, with ferritin levels in the normal range for the United Kingdom
(UK; 15–300 µg/L for men and 15–200 µg/L for women) according to Dooley and Wor-
wood, and Fitzsimons and colleagues [41,42]. Any prospective participants with deficient
haemoglobin (HGB) levels (<130 g/L for men and <120 g/L for women) were not eligible
for inclusion in the study [5].
Participants were excluded from the trial if they had any diagnosis of medical con-
dition or comorbidities as per the exclusion criteria (such as, currently trying to conceive,
pregnant, lactating, experiencing any chronic menstrual disorders, or reported undergo-
ing any menopausal changes). Additionally, participants were excluded if they had any
issues related to oral supplement ingestion; were on any medication or supplementation; if
their alcohol consumption exceeded 21 units/week; or if they experienced any chronic GI
symptoms, eating disorders, psychological conditions, or any hypo/hypertensive blood
pressure (BP) measurements [43,44].
2.4. Safety Screening
All potential study participants were screened during a medical history interview for
health conditions that may preclude participation in the study, conducted in 2018–2019,
with respect to the inclusion/exclusion criteria. Interviews were supported with the use of
the General Symptoms Questionnaire (GSQ-65). All participants were interviewed for a
duration of 60 min and included the use of open-ended questions to gain comprehensive
understanding of their health status. Furthermore, a fasting (12 h, overnight) blood sample
was collected (for ferritin and full blood count analysis) and BP was measured using
Omron M6 Comfort blood pressure monitor, (Omron, Hoofddorp, The Netherlands).
Participants were not enrolled if anomalous results or findings from the safety screening
were established.
2.5. Participants
Study participants were randomly allocated to one of five different treatment groups
using blocked, gender balanced randomisation (with 31 participants in each group) using
the Study Randomizer software [38]. The five different treatment groups were ferrous
sulphate placebo + curcumin placebo (FS0_Plac), ferrous sulphate–18 mg elemental iron +
placebo (FS18_Plac), ferrous sulphate–18 mg elemental iron + 500 mg curcumin (FS18_Curc),
ferrous sulphate–65 mg elemental iron + placebo (FS65_Plac), and ferrous sulphate–65 mg
elemental iron +500 mg curcumin (FS65_Curc) (Figure 1).




Figure 1. Study design. Random allocation to treatment groups post safety screening (n = 31/group). At baseline (0 min), 
both body measurements and blood samples were collected. At end-point (180 min), only blood samples were collected. 
2.6. Supplements 
Participants were provided with two different doses of ferrous sulphate iron sup-
plements depending on the group they were randomized to. The higher dose of ferrous 
sulphate was 200 mg with 65 mg elemental iron and is based upon the traditional first 
line oral iron therapy for treatment and prophylaxis of ID and ID anaemia generally 
used worldwide [45]. The lower dose was 55 mg ferrous sulphate containing 18 mg ele-
mental iron, based upon the recommended Daily Value (DV) of iron as per the US Food 
and Drug Administration (FDA) [45,46]. Formulated curcumin supplement (Hydro-
Curc™, Pharmako Biotechnologies Pty Ltd. New South Wales, Australia) included 
500mg/day comprising of 80% curcumin, 17% DMC, and 3% BDMC (~85% total curcu-
minoids), entrapped in a patented delivery system (LipiSperse®) [47]. For the placebo, 
microcrystalline cellulose was used. This cellulose was also used as an inert bulking 
agent in the capsules of active ingredients. The ferrous sulphate and curcumin supple-
ments were packed into white-opaque hydroxypropyl methylcellulose (HPMC) capsules 
(sizes used were #1 and #00). Participants were provided with one ferrous sulphate iron 
at 0 min and with one curcumin supplement 60 min after the iron supplement on the 
day of the trial, in the fasted state, by trained research staff. 
2.7. Physical Examination 
Blood pressure was measured by a trained research associate or research assistant 
as described in the safety screening section. Anthropometric measurements were collect-
ed on the day of the study (baseline measures) by trained research staff. Height was 
measured to the nearest millimeter (without shoes) using a Seca 247 stadiometer (Seca 
GmbH & Co. KG, Hamburg, Germany). Weight, body mass index (BMI), and body fat % 
were measured using Seca mBCA 515 medical Body Composition Analyzer (Seca GmbH 
& Co. KG, Hamburg, Germany). Care was taken to instruct participants to void bladder 
of urine, empty pockets, and remove any excessive clothing and any jewellery prior to 
all measurements. Waist circumference was obtained using a soft tape measure at the 
narrowest point between the lower rib and the top of the hip bone.  
Figure 1. Study design. Random allocation to treatment groups post afety screeni g (n = 31/group). At baseline (0 min),
both body measurements and blood samples wer collected. At end-point (180 min), only blood samples wer collected.
2.6. Supplements
Participants were provided with two different doses of ferrous sulphate iron sup-
plements depending on the group they were randomized to. The higher dose of ferrous
sulphate was 20 mg with 65 mg el mental iron and is based upon the traditional first
line oral iron therapy for treatment a d prophylaxis of ID and ID anaemia g nerally used
worl wide [45]. The lower d se was 55 mg ferrous sulphate cont ining 18 mg elemental
iron, b sed upon the recommended Daily Value (DV) of iron as per the US Food and
Drug Administration (FDA) [45,46]. Formulated curcumin supplement (HydroCurc™,
Pharmako Biotechnologies Pty Ltd. New South Wales, A strali ) included 500 mg/day
comprising of 80% curcumin, 17% DMC, and 3% BDMC (~85% total curcumin ids), en-
trapped in a patented delivery sys m (LipiSperse®) [47]. For the placebo, mic ocrystalline
cellulose was us d. This cellulo e was also used as an inert bulking agent i th capsules
of active ingredients. The ferrous sulphate and curcumin sup lements were packed into
white-opaque hydroxypropyl methylcellulose (HPMC) capsules (sizes used were #1 and
#00). Participants were provided with one fer ous sulphate iron at 0 min and with one
curcu in supplement 60 min after the iron supplement on the day of the trial, in the fasted
state, by trained research staff.
2.7. Physical Examination
Blood pressure was measured by a trained research associate or research assistant as
described in the safety screening section. Anthropometric measurements were collected on
the day of the study (baseline measures) by trained research staff. Height was measured
to the nearest millimeter (without shoes) using a Seca 247 stadiometer (Seca GmbH &
Co. KG, Hamburg, Germany). Weight, body mass index (BMI), and body fat % were
measured using Seca mBCA 515 medical Body Composition Analyzer (Seca GmbH &
Co. KG, Hamburg, Germany). Care was taken to instruct participants to void bladder
of urine, empty pockets, and remove any excessive clothing and any jewellery prior to
all measurements. Waist circumference was obtained using a soft tape measure at the
narrowest point between the lower rib and the top of the hip bone.
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2.8. Blood Sample Collection and Processing
Blood tests were carried out for each participant, following an overnight fast (12-h
fast). Venous blood samples were collected (by certified phlebotomists) by venipuncture
(from the antecubital fossa) using a 21G needle, at time 0 min and 180 min after iron
supplementation. Approximately 10 mL of blood was collected from each participant using
a Becton Dickinson (BD) Vacutainer® serum-separating tube (SST) and a BD Vacutainer®
ethylenediamine tetra-acetic acid (EDTA) tube (BD, Oxford, UK). Blood in the SSTs were
left to coagulate at room temperature for 45 min and then centrifuged (Hettich 340r, Hettich
GmbH & Co. KG, Tuttlingen, Germany). To render samples acellular, centrifugation was
performed for 10 min at 5000 rpm/3857× g at 4 ◦C. Post centrifugation, aliquots of serum
supernatant were stored at −80 ◦C in 1.5 mL microcentrifuge tubes. The EDTA tubes were
kept on ice prior to whole blood analysis (on the day of collection) and then centrifuged for
10 min at 3857× g at 4 ◦C. Similarly, post centrifugation, aliquots of plasma supernatant
were stored at −80 ◦C immediately.
2.9. Analysis of Serum Ferritin Concentration
Serum ferritin samples were defrosted and analysed using a Horiba ABX Pentra 400
(Horiba Ltd., Kyoto, Japan) multiparametric medical bench top chemistry analyser and
the Horiba ABX Pentra CRP CP High Sensitivity and ABX Ferritin 2 CP reagents. This
chemistry analyser is compliant with the National Committee for Clinical Laboratory
Standards (NCCLS) [48]. In accordance with the manufactures processes, ferritin levels
were determined by latex-enhanced immunoturbidimetric assay [49].
2.10. Analysis of Serum Iron Profile
Serum iron, total iron binding capacity (TIBC), transferrin saturation (TS), and unsatu-
rated iron-binding capacity (UIBC) were assessed externally (using necessary standards
and controls for each analyte) at Health Services laboratories (HSL Analytics LLP, London,
UK); Project No. P197 as primary outcome measures of this study. Serum iron and UIBC
were measured by direct colorimetric method, and subsequently, serum TIBC and TS were
calculated using the equations from Elsayed et al. [50]:
TIBC = serum iron + UIBC
TS = serum iron/(serum iron +UIBC) × 100
2.11. Analysis of Whole Blood Haemoglobin (HGB) Concentration
HGB, a secondary outcome measure, was analysed using the Sysmex XP-300 (Sys-
mex Corporation, Kobe, Japan) automated haematology analyser. The Sysmex XP-300 is
compliant with International Standards Organisation (ISO)/International Electrotechnical
Commission (IEC) 17043:2010, via the Sysmex Network Communication Service. The Sys-
mex instrument aspirated 50 µL of each sample. HGB was analysed using a non-cyanide
haemoglobin detection method [51]. The XP-300 was calibrated by Sysmex Corporation
according to the manufacturer’s specifications, and quality was guaranteed using Sysmex
internal quality control.
2.12. Analysis of Serum Thiobarbituric Acid Reactive Substances (TBARS) Concentration
Serum TBARS were determined by TBARS parameter assay kit (R&D Systems, Min-
neapolis, MN, USA), with a sensitivity of 0.007–0.055 µM minimum detectable dose range
as another secondary outcome measure of the study. The assay procedure was performed
according to the manufacturer’s instructions and plates were read using a microplate reader
(SPECTROstar® Nano, BMG Labtech GmbH, Ortenberg, Germany) at the absorbance of
530 nm.
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2.13. Statistical Analysis
Values are expressed as mean ± Standard Error of Mean (SEM). All parameters
were checked for normality using Shapiro–Wilk (S-W) tests, and results were statistically
analysed using a two-way, repeated measures analysis of variance (ANOVA) or mixed
effects model [52–54]. Post-hoc tests (Sidak’s and Tukey’s) were applied to assess differences
between and within treatment groups with multiplicity adjusted P values reported for
each comparison. Data analysis was carried out using PRISM software package (Version 9,
Graphpad Software Inc., San Diego, CA, USA) and IBM Statistical Package for the Social
Sciences (SPSS, Version 25.0, IBM Corp., New York, NY, USA).
3. Results
3.1. Participant Characteristics
Of the 155 participants that started the study, there were 79 males (26.42 years ±
0.55) and 76 females (25.82 years ± 0.54). Participant 105 was excluded from further
analysis (Figure S1) due to BMI of 49.65 kg/m2, the only BMI that fell in class 3 obese
category (≥40 kg/m2) [55,56] and the only value detected as 3*IQR or an extreme outlier
in SPSS. The age of participants ranged from 19 to 39 years of age. Overall, the mean age
of the included 154 participants was 26.12 years (± 0.39). In addition, mean height was
1.71 m (±0.01), and mean weight was 68.93 kg (± 1.13). Anthropometric characteristics of
participants within each of the five treatment groups are presented in Table 1.
Table 1. Anthropometric characteristics of participants split by gender.
Characteristics FS0_Plac FS18_Plac FS18_Curc FS65_Plac FS65_Curc Total


































































































































(n = 15) (n = 15) (n = 18) (n = 12) (n = 15) (n =15) (n = 13) (n = 17) (n = 17) (n = 14) (n = 78) (n = 73)
Values presented in mean ± standard error of mean (SEM).
3.2. Baseline Levels of Assessed Biomarkers
Baseline comparisons between each of the supplementation groups showed no statis-
tical difference in any of the measured biological marker levels.
3.3. Effects of Acute Supplementation on Serum Iron Levels
When assessing the effects of each treatment within the groups, there was a significant
difference observed over time (F (1, 144) = 331.9, p < 0.0001) with statistically significant
intra-group increases in mean serum iron after 180 min (p < 0.0001) in the FS18_Plac,
FS18_Curc, FS65_Plac, and FS65_Curc groups. The lower dose groups, FS18_Curc and the
corresponding curcumin placebo group FS18_Plac, after 180 min, had a 11.41 µmol/L and
8.79 µmol/L increase in serum iron, respectively. The higher dose groups, FS65_Curc and
the corresponding iron and placebo group FS65_Plac, after 180 min, had 16.39 µmol/L
and 19.09 µmol/L increase in serum iron, respectively. There was no significant increase
observed in the FS0_Plac group (Figure 2).
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Figure 2. Serum iron l vels at baseline and 180 min following supplementation. Results ar
presented as mean ± SEM Serum iron levels (µmol/L). ns indicates no significant difference
(p > 0.05); * represents significance values when comparing time points within the same the condi-
tions (**** p < 0.0001).
Inter-group analysis of serum iron l vels at 180 min showed significant between group
difference (F (4, 149) = 10.73, p ≤ 0.0001). Statistically significant differences were observed
between each treatment group except FS18_Plac vs. FS18_Curc, FS18_Curc vs. FS65_Curc
and FS65_Plac vs. FS65_Curc (Table 2).
Table 2. Inter-group differences in serum iron levels (µmol/L) at 180 min.
Groups MD ± SED Sig. * p-Value
FS0_Plac vs. FS18_Plac −7.18 ± 2.18 ** 0.0096
FS0_Plac vs. FS18_Curc 10.02 ± 2.16 **** <0.0001
FS0_Plac vs. FS65_Plac 19.88 ± 2.17 **** < 0.0001
FS0_Plac vs. FS65_Curc 15.63 ± 2.16 *** <0.0 01
FS18_Plac vs. FS18_Curc 2.84 ± 2.19 NS 0.6917
FS18_Plac vs. FS65_Plac 12.71 ± 2.19 **** <0.0 01
FS18_Plac vs. FS65_Curc −8.45 ± 2.19 ** 0.0013
FS18_Curc vs. FS65_Plac −9.86 ± 2.18 **** <0.0001
FS18_Curc vs. FS65_Curc −5.61 ± 2.18 NS 0.0771
FS65_Plac vs. FS65_Curc 4.25 ± 2.18 NS 0.2935
Results presented as mean difference (MD) ± standard error of difference (SED). Sig.* represents significance
values when comparing groups at the same timepoint (** p < 0.01, **** p < 0.0001, NS p > 0.05).
3.4. Effects of Acute Supplementation on Serum TIBC Levels
When evaluating the effect of treatment group on serum TIBC levels after 180 min of
supplementation, a significant difference was observed between the two time points (F (1,
137) = 19.76, p < 0.0001). A significant increase of 2.36 µmol/L (p = 0.0102) and 2.11 µmol/L
(p = 0.0406) in TIBC levels from baseline to end-point was observed in the treatment groups
FS0_Plac and FS18_Plac, respectively. There was no significant difference observed within
the rest of treatment groups (FS18_Curc, FS65_Plac and FS65_Curc) over time (Figure 3).
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When assessing the effects of each treatment on serum TS after 180 min of 
supplementation, a within group statistically significant difference was observed (F (1, 
137) = 308.4, p < 0.0001). There were statistically significant (p < 0.0001) increases of 
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Figur 4. Effect of 180 min supplementation on mean serum uns turated iron-binding capacity
(UIBC, µmol/L) levels (mean, SEM). * represents significance values when comparing time points
within the same the conditions (*** p = 0.0002, **** p < 0.0001); ns indicates no significant difference
(p > 0.05).
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When assessing the effects of each treatment on UIBC levels between groups at
180 min, a significant difference (F (4, 148) = 7.226, p < 0.0001) was detected. Statistically
significant differences were observed between each treatment group except FS0_Plac vs
FS18_Curc, FS18_Plac vs FS18_Curc, and FS65_Plac vs FS65_Curc (Table 3).
Table 3. Inter-group differences in serum unsaturated iron-binding capacity (UIBC) levels (µmol/L)
at 180 min.
Groups MD ± SED Sig. * p-Value
FS0_Plac vs. FS18_Plac 4.57 ± 2.80 NS 0.4782
FS0_Plac vs. FS18_Curc 9.56 ± 2.78 ** 0.0062
FS0_Plac vs. FS65_Plac 19.43 ± 2.83 **** <0.0001
FS0_Plac vs. FS65_Curc 18.10 ± 2.81 **** <0.0001
FS18_Plac vs. FS18_Curc 4.99 ± 2.83 NS 0.3944
FS18_Plac vs. FS65_Plac 7.00 ± 2.86 **** <0.0001
FS18_Plac vs. FS65_Curc 13.53 ± 2.85 **** <0.0001
FS18_Curc vs. FS65_Plac 9.87 ± 2.85 ** 0.0055
FS18_Curc vs. FS65_Curc 8.54 ± 2.84 * 0.0235
FS65_Plac vs. FS65_Curc −1.33 ± 2.87 NS 0.9906
Results presented as mean difference (MD) ± standard error of difference (SED). Sig.* represents significance
values when comparing groups at the same timepoint (* p < 0.05, ** p < 0.01, **** p < 0.0001, NS p > 0.05).
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p < 0.0001). There were statistically significant (p < 0.0001) increases of 12.77%, 17.24%,
30.00%, and 27.96% in TS observed in the FS18_Plac, FS18_Curc, FS65_Plac, and FS65_Curc,
respectively. There was no significant increase observed in the FS0_Plac group over time
(Figure 5).
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FS18_Plac vs. FS65_Curc −19.14 ± 3.85 **** <0.0001 
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3.7. Effects of Acute Supplementation on Whole Blood HGB Levels 
When evaluating the effect of treatment group on whole blood HGB levels after 180 
min of supplementation, a significant difference was observed between the two time 
points (F (1, 147) = 22.35, p < 0.0001). A significant increase of 1.55%/2.04 g/L in HGB lev-
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Figur 5. Effect of 180 in supplementation o mean serum transferri saturation (TS) % (mean,
SEM). * represents significance values when comparing time points within the same the conditions
(**** p < 0.0001); ns represents no significant difference (p > 0.05).
When assessi g the inte -group effects of each tretament on TS at 180 min, a ign ficant
difference (F (4, 148) = 10.39, p < 0.0001) was detected. Statistically significant differences
were observed between each treatment groups except FS0_Plac vs. FS18_Curc, FS18_Plac
vs. FS18_Curc, and FS65_Plac vs. FS65_Curc (Table 4).
Nutrients 2021, 13, 2300 10 of 15
Table 4. Inter-group differences in transferrin saturation (TS %) at 180 min.
Groups MD ± SED Sig. * p-Value
FS0_Plac vs. FS18_Plac −10.06 ± 3.78 NS 0.0627
FS0_Plac vs. FS18_Curc −16.30 ± 3.76 *** 0.0002
FS0_Plac vs. FS65_Plac −32.20 ± 3.82 **** <0.0001
FS0_Plac vs. FS65_Curc −29.21± 3.80 **** <0.0001
FS18_Plac vs. FS18_Curc −6.24 ± 3.82 NS 0.4772
FS18_Plac vs. FS65_Plac −22.14 ± 3.88 **** <0.0001
FS18_Plac vs. FS65_Curc −19.14 ± 3.85 **** <0.0001
FS18_Curc vs. FS65_Plac −15.90 ± 3.86 *** 0.0005
FS18_Curc vs. FS65_Curc −12.90 ± 3.83 ** 0.0077
FS65_Plac vs. FS65_Curc 2.99 ± 3.89 NS 0.9388
Results presented as mean difference (MD) ± standard error of difference (SED). Sig.* represents significance
values when comparing groups at the same timepoint (** p < 0.01, *** p < 0.001, **** p < 0.0001, NS p > 0.05).
3.7. Effects of Acute Supplementation on Whole Blood HGB Levels
When evaluating the effect of treatment group on whole blood HGB levels after
180 min of supplementation, a significant difference was observed between the two time
points (F (1, 147) = 22.35, p < 0.0001). A significant increase of 1.55%/2.04 g/L in HGB
levels from baseline to end-point (180 min) was observed in participants taking FS65_Curc
(* p < 0.05) (Figure 6 and Figure S2).
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sults. In murine models, it was shown that curcumin decreases systemic iron levels 
when administered consistently over several months [31,62,63]. Curcumin was shown to 
moderately chelate iron-forming insoluble complexes that may influence iron absorption 
in the gut, although this has largely been shown in in-vitro studies [64]. 
In the current study, co-administration of ferrous iron and curcumin in the form of 
HydroCurc™ does not negatively affect iron absorption compared to ferrous iron alone. 
Mean increases in serum iron after 180 min, in both FS65_Plac and FS65_Curc, are in line 
with expected increases in the literature [65–68]. Furthermore, HGB levels were also sig-
nificantly elevated at 180 min compared to baseline in the group receiving the high iron 
Figure 6. Haemoglobin (HGB) levels are expressed as percentage difference compared to baseline
levels (SEM). * repres nts significant difference over time (* p < 0.05).
There was no significant difference observed between treatment groups after 180 min
of supplementation (F (4, 149) = 0.1042, p = 0.9809).
3.8. Effects of Acute Supplementation on Serum TBARS Levels
There were no significant intra- (F (1, 144) = 0.1889, p = 0.6645) or inter-group (F (4,
149) = 0.9583, p = 0.4323) differences observed in TBARS levels (level of oxidative stress) in
this acute study as a result of iron and curcumin co-administration after 180 min.
4. Discussion
The polyphenol curcumin has been purported to have many health benefits as a
result of its potential to target numerous signaling avenues and its impact on cellular
level activity [57]. Despite its significant therapeutic potential, the pharmacological use
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of curcumin has been limited due to its poor bioavailability, limited bio-distribution,
poor stability, and short activity half-life [58]. Formulation science strategies have shown
that carrier-based delivery systems such as liposomes and micelles may address these
limitations and enhance curcumin’s therapeutic potential [59–61]. This study utilised
curcumin supplement in the form of HydroCurc™, a formulation consisting of 85% total
curcuminoids entrapped in a proprietary delivery system (LipiSperse®) that has been
shown to enhance bioavailability in humans [47].
Studies assessing the effects of curcumin on iron levels have provided mixed results.
In murine models, it was shown that curcumin decreases systemic iron levels when admin-
istered consistently over several months [31,62,63]. Curcumin was shown to moderately
chelate iron-forming insoluble complexes that may influence iron absorption in the gut,
although this has largely been shown in in-vitro studies [64].
In the current study, co-administration of ferrous iron and curcumin in the form of
HydroCurc™ does not negatively affect iron absorption compared to ferrous iron alone.
Mean increases in serum iron after 180 min, in both FS65_Plac and FS65_Curc, are in
line with expected increases in the literature [65–68]. Furthermore, HGB levels were also
significantly elevated at 180 min compared to baseline in the group receiving the high
iron dose of 65 mg ferrous sulphate with HydroCurc™. HGB increases can result from
dehydration or a reduction in the plasma vascular fraction [69]. However, this is unlikely
to explain the resulting increase in HGB levels as all participants across the study were
given free access to drinking water ad libitum.
Current understanding of iron homeostasis indicates that iron absorbed via the GI
tract would first need to pass through the liver and bone marrow, before being incorporated
into HGB during erythropoiesis [70]. However, this seems unlikely to explain the result in
the current study given the short time frame of 180 min (3 h). Longitudinal research into
iron supplementation, lasting several weeks (rather than hours), demonstrated significantly
increased HGB levels in mildly anaemic populations [71]. However, the authors of the
current study did not find any studies reporting acute changes (within 3 h) in HGB levels
in a healthy population with normal serum levels. Although the researchers cannot rule
out the possibility that this acute change is due to a physiological process, it cannot
be explained based on current understanding of iron incorporation into HGB during
erythropoiesis [70]. This outcome presents an intriguing avenue for in-depth exploration
in further investigations.
The current study used serum iron analysis to evaluate iron absorption, as it increases
in response to changes in dietary intakes of iron [3]. Dietary non-haem iron, typically found
in the ferric (Fe3+) iron form, is oxidised into absorbable soluble ferrous (Fe2+) iron in the
gastric and intestinal pH environment [72,73]. Given reports of diurnal changes in serum
iron concentrations [74–76] and previous recommendations to standardize sampling [50],
all participants’ baseline measures of serum iron were assessed in the morning following
an overnight fast (12 h fast). Following randomization, all participants were observed
to take oral ferrous sulphate on an empty stomach with water only (to circumvent any
confounding effect of dietary components, which could influence iron absorption in an
acute absorption test) [68]. To assess acute iron absorption from ferrous sulphate, it is
advised to administer a dose yielding 65 mg of elemental iron and assess serum iron at
2–3 h post supplementation [67,68]. This method is used to evaluate gut iron absorption in
humans [68,77,78]. If gut iron absorption is adequate, there is approximately a 17.9 µmol/L
increase in serum iron levels as suggested by Alleyne et al. [68] or an increase of two to
three times above baseline levels [67].
The current study also demonstrates that the increases in serum iron are translated
into an increase in iron transportation via transferrin saturation levels. All groups receiving
iron demonstrated an increase in transferrin saturation (TS%) and in a dose-related manner.
Clinically, this measure is used as an indicator of iron-related diseases such as iron overload
e.g., haemochromatosis or iron insufficiency e.g., iron deficiency anaemia [50]. However,
in the current study, transferrin saturation (%) is an indicator of the saturation in iron
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transport capacity between different treatments and iron doses. Interestingly, there were no
differences in transferrin saturation in the presence of HydroCurc™ compared to iron alone
at either dose of iron. This finding indicates that HydroCurc™ has no effect on iron uptake
or bioavailability at low or high doses of iron. Additionally, the dose response differences
in transferrin saturation (%) as well as unsaturated iron binding capacity (UIBC) between
the 18 mg and 65 mg groups indicates additional reserve capacity in the iron metabolism
pathways in healthy participants to mobilise different doses of iron.
5. Conclusions
In the current study, regardless of ferrous dose (18 mg or 65 mg iron), formulated
curcumin in the form of HydroCurc™ does not inhibit ferrous iron absorption following
ingestion. Furthermore, the significant increase in HGB levels observed in the FS65_Plac
group is retained in the FS65_Curc group, demonstrating that the serum iron levels result
in a measurable physiological effect that is not diminished by the addition of formulated
curcumin. To the best knowledge of the authors, this study has demonstrated for the
first time that formulated curcumin does not appear to negatively influence acute iron
absorption in healthy humans.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/nu13072300/s1, Figure S1: The study compliance after 155 participants were enrolled and
randomised equally into 5 treatment groups; Figure S2: Effect of 180 min supplementation on mean
Haemoglobin (HGB) levels.
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